## Topical Treatment of Basal Cell Carcinoma **Key Point:** Imiquimod is the FDA-approved and preferred topical agent for non-nodular, non-infiltrative basal cell carcinoma, particularly in patients who are poor surgical candidates or have multiple lesions. ### Mechanism of Imiquimod Imiquimod is a toll-like receptor 7 (TLR-7) agonist that: 1. Activates innate immunity via dendritic cells and macrophages 2. Induces interferon-alpha and tumor necrosis factor-alpha production 3. Promotes apoptosis of malignant keratinocytes 4. Enhances local cell-mediated immunity against tumor cells ### Efficacy and Application **High-Yield:** Imiquimod shows 80–90% clearance rates for superficial and nodular BCC when applied 5 times weekly for 6–12 weeks. **Clinical Pearl:** Imiquimod is particularly effective for: - Superficial BCC (highest cure rates) - Nodular BCC (moderate cure rates) - Multiple lesions in immunocompromised patients - Lesions in cosmetically sensitive areas (face, eyelids) ### Comparison with Other Topical Agents | Agent | Mechanism | BCC Efficacy | Indication | |-------|-----------|--------------|------------| | **Imiquimod** | TLR-7 agonist | 80–90% (superficial) | First-line topical; non-nodular BCC | | **5-Fluorouracil** | Antimetabolite | 60–80% | Superficial BCC; adjunct post-surgery | | **Tretinoin** | Retinoid | Not established | Photoaging, actinic keratosis (not BCC) | | **Hydroquinone** | Melanin inhibitor | None | Melasma, post-inflammatory hyperpigmentation | **Warning:** Imiquimod is NOT suitable for infiltrative or morpheaform BCC subtypes, which have lower cure rates and higher recurrence risk. ### Adverse Effects of Imiquimod - Local: erythema, erosion, crusting, pruritus (expected and dose-dependent) - Systemic: flu-like symptoms, fatigue (rare) - Hyperpigmentation or hypopigmentation at treatment site ### Treatment Protocol **Tip:** Standard dosing is 5 times per week (e.g., Monday–Friday) for 6–12 weeks. Patients should be counseled that local inflammation is a sign of immune activation, not toxicity. [cite:Bolognia Dermatology 4e Ch 124]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.